Investigation of adalimumab on quality of life in 302 patients with moderate to severe rheumatoid arthritis
ZHANG Ya-mei
ZHAO Juan
GAO Qing-hua
ZHAO Zheng
HUANG Feng
Abstract：Objective:To explore the effect of adalimumab on quality of life (QOL) of patients with moderate to severe rheumatoid arthritis. Methods:A total of 302 patients with rheumatoid arthritis were given adalimumab intervention for 24 weeks. A randomized, double-blind placebo-controlled study was carried out in the ifrst 12 weeks, and the patients were divided into three groups, adalimumab 40 mg group, adalimumab 80 mg group, placebo group. The following 12 weeks was a open study, all the patients received subcutaneous administration of adalimumab 40 mg, once every two weeks. The QOL of each patient before and after intervention was assessed and compared by using SF-36 scale. Results:After intervention, physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, mental health were improved signiifcantly. Conclusion:Adalimumab helps to improve the QOL of patients with rheumatoid arthritis.
Keywords：Rheumatoid arthritisQuality of lifeCurative effectAnalysisAdalimumab
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 120-123 )